Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

NCT05733598 is registered in ClinicalTrials.gov with Replimune, Inc. as lead sponsor.

NCT NCT05733598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05733598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma
Lead sponsor
Replimune, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2024
Completion date
July 1, 2028
Enrollment
60 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, hepatocellular carcinoma